



New Hampshire Department of Health & Human Services
Independent Clinical Reviews

OFFICIAL RESPONSES TO VENDOR QUESTIONS
RFP-2017-OMBP-02-INDEP

No.	Question	Answer
1)	Section 1.1: What is entailed in 'consultation regarding medical claims reviews?'	Consultation regarding medical claims review is providing access to specialty and subspecialty physician clinical expertise to conduct reviews of specific Medicaid cases. Reviews can include (1) appropriateness for medical or pharmacy services or treatment, or (2) Medicaid program eligibility.
2)	Section 3.2.1: What specialties have been required for the last 2 years of cases?	Specialties used in the past 2 years are: <ul style="list-style-type: none">• Dermatology• Endocrinology• Gastroenterology• Internal Medicine• Neurology• Ophthalmology• Psychiatry• Pulmonology
3)	Section 3.2.2.3: Can you explain what you mean by 'other Medicaid benefit management initiatives?'	Other Medicaid benefit management initiatives may include consultation on the use of: prior authorization requirements on specific drugs or classes, quantity limits, step therapy requirements, preferred drug list classes or appropriate medical need for services, whether covered by the NH Medicaid program or uncovered.
4)	Section 3.2.4.1: a) What is involved in a routine preferred drug list ratification review? b) What is the Department	Preferred Drug List reviews involve how the drug is used in clinical practice and should reflect the evidenced-based, peer reviewed, published medical literature. These reviews do not involve patient specific information. The purpose of this review is to ratify the NH Medicaid's Drug Use Review Board's selections to the Preferred Drug List. Ratification is the final quality check to assure preferred agents will meet



New Hampshire Department of Health & Human Services Independent Clinical Reviews

No.	Question	Answer
	looking for from the Contractor in a routine preferred drug list ratification review?	the first line clinical needs of the majority of NH Medicaid recipients utilizing the indicated therapeutic class. Information provided would include a copy of the NH law that outlines the requirements of this process; a description of the selection process; a definition of therapeutic alternative; the current Preferred Drug list and the Preferred Drug List exception criteria.
5)	Section 3.2.6.3: a) What is involved in follow-ups to completed reviews? b) When would these occur?	A follow-up would only be necessary if the State requires clarification on a completed review or has further questions.
6)	Section 3.2.7: Can you please provide the number of reviews performed in 2014 and 2015?	37 reviews were performed in 2014 and 2015.
7)	Section 7.2.2.8: Are there any formatting requirements for Letters of Commitment from any subcontractors?	Letters of Commitment must be on subcontractor letterhead.
8)	Section 7.2.2.11.2: Will the Department provide data for eligible persons for the program, including LEP persons (past & present) for vendors to use in completing their evaluation in Appendix D?	No
9)	Section 8.1.1: Is the bidder supposed to fill out	No. Appendix B is a reference document for vendor use in completing Appendix A.



New Hampshire Department of Health & Human Services Independent Clinical Reviews

No.	Question	Answer
	page 1 of Appendix B and initial all remaining pages of the appendix?	
10)	General: a) Who is the incumbent on the current project? b) How long have they been in this role?	Network Medical Review Company, Limited was awarded this contract in 2009.
11)	General: What is the value of the current contract?	The contract is available on-line at http://www.nh.gov/council/meetings/index.htm . The contract was approved at the April 23, 2014 Governor and Executive Council Meeting (Item #35).
12)	General: What are the present rates the State is paying?	The contract is available on-line at http://www.nh.gov/council/meetings/index.htm . The contract was approved at the April 23, 2014 Governor and Executive Council Meeting (Item #35).
13)	General: How many pages are in the files for each case on average?	A routine drug review for PDL ratification is usually 3 pages long. Case review files vary in length dependent upon documentation provided.
14)	General: What was the total expenditure for this program in each of the last 2 years?	The contract is available on-line at http://www.nh.gov/council/meetings/index.htm . The contract was approved at the April 23, 2014 Governor and Executive Council Meeting (Item #35).